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ABSTRACT

Glucose transport was assessed in vascular smooth muscle (VSM) cells by measuring
the uptake of a radiolabeled non-metabolizable glucose analog, [3H]-2-deoxglucose. VSM

cells, isolated from rat aortae by enzymatic digestion, were maintained in culture in
Dulbecco's Modified Eagle Medium supplemented with 10% newborn calf serum at 37°C
with 5% CO2 and air. Angiotensin II (AU) increased glucose transport by 84%. Significant
stimulation occurred by two hours of exposure with the maximum effect being observed

between six and eight hours. All effects were concentration dependent with a threshold
response being detected at 0.1 nM. All-stimulated transport was blocked by an AU receptor

antagonist.

AII stimulation was shown to require protein synthesis. A specific protein

synthesized in response to AII stimulation was the GLUT 1 glucose transporter as assessed
by western blot analysis, using an antibody generated against the carboxyl terminus of the

GLUT 1 transporter. Protein kinase C (PKC) stimulation with phorbol esters significantly
increased glucose uptake.

The majority of evidence from PKC inhibition and

downregulation studies however, suggest AU is capable of stimulating glucose transport

through a PKC-independent mechanism. Extracellular calcium and calmodulin appear to be
required for AU stimulation of glucose transport. Hyperglycemic conditions reduced basal
glucose transport. The maximum rate of All-stimulated transport was not appreciably altered

by the glycemic state; however, the relative effectiveness of AII at different concentrations

of glucose varied with media glucose concentration.
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LITERATURE REVIEW

Essential hypertension is a condition of raised arterial pressure characterized by

increased peripheral resistance and medial vascular hypertrophy. Hypertension is prevalent

in the United States and other industrialized nations affecting 15 - 20 % of the adult
population (James and Baker, 1995). Hypertensive individuals have a higher than average

risk of developing coronary heart disease, heart failure, stroke, kidney disease, renal failure,

atherosclerosis, and myocardial infarction (Wilson and Kannel, 1995; Davis et al., 1977).
On examining the prevalence and consequences of essential hypertension, the importance

of understanding the mechanisms involved in initiating and maintaining this condition and
of studying potential treatment regimens that may be successful in its control becomes

exceedingly clear.
Essential hypertension was described in 1836 by Richard Bright who noted left

ventricular hypertrophy of the heart and aortic wall thickening (medial hypertrophy)
associated with this condition (Folkow, 1982). Later, in 1868, George Johnson observed

wall thickening of arterioles, a finding later confirmed by Ewald in 1877 (Folkow, 1982).
While these initial descriptions were hallmarks in hypertension research, further advances

in understanding the pathogenesis of hypertension were not possible without an appropriate

animal model of essential hypertension in humans. Harry Goldblatt provided the first
successful animal model that was reasonably similar to essential hypertension in man in the

early 1930's. Dr. Goldblatt was able to induce hypertension in dogs by clamping the renal
artery of one kidney and either removing or leaving intact the contralateral kidney (Goldblatt
1
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et al., 1934). The former model was referred to as one-kidney, one-clip renovascular

hypertension and the latter as two-kidney, one-clip renovascular hypertension. The Goldblatt

model lead to the discovery of angiotensin by Braun-Menendez and colleagues in 1939 and
Page and Helmer in 1940 (Fasciolo, 1990; Page and Helmer, 1940), as well as many other
advances in hypertension research. Other models of experimentally induced hypertension

now exist, including the DOC/salt model, the aortic coarctation model, and a genetic model

known as the spontaneously hypertensive rat (SHR).
DOC-induced hypertension in animals was first described in 1939 by Loeb after

discovering that treatment of patients having Addison's disease with synthetic

deoxycorticosterone (DOC) or its acetate (DOCA) led to hypertension (Loeb et al., 1939;

Ryan and McCullagh, 1940; Thorn et al., 1942). His results were later confirmed in dogs
(Swingle et al., 1941) and rats (Grollman et al., 1940). Selye and colleagues (1943)
described hypertension resulting from DOCA in conjunction with a high salt diet in rats,

dogs, and monkeys. Further studies have demonstrated that DOCA-induced hypertension
in rats requires a sodium component (Brownie, 1995). In the DOC/salt model, hypertension

is induced by treating rats with deoxycorticosterone (DOC), a mineralocorticoid, and
providing saline as the sole drinking fluid. Mineralocorticoids act at the level of the kidney

to stimulate sodium and water reabsorption. In this model there is an initial rise in plasma
volume and blood pressure. The increase in blood pressure is maintained with continued
DOC/salt treatment. The precise mechanism leading to the development of hypertension in

this model is unclear.

2

The aortic coarctation (also referred to as aortic stenosis or ligature) model of

hypertension is unique in providing a means of studying the hypertensive process in vascular
beds independent of high intravascular pressure. In this model, a small metal clip is placed
around the aorta, above the renal arteries, to restrict blood flow. High arterial blood pressure
occurs above the clip while normal blood pressure occurs below the point of coarctation.

Using this model, several investigators have observed increased wall thickness of the

normotensive abdominal aorta (Overbeck, 1979) and an increase in arterial resistance in the
normotensive hindlimb vascular bed under resting conditions (Nolla-Panades, 1963) as well
as conditions of maximal vasodilation (Bell and Overbeck, 1979). In addition, Plunkett and

Overbeck (1985) noticed an increase in wall thickness and the wall-to-lumen ratio in
arterioles of the normotensive cremaster vascular bed. These results provide indirect

evidence that vascular structural changes have occurred independent of high intravascular

pressure in coarctation-induced hypertension. Although interesting, these results have to be

interpreted with caution because contradictory evidence has been obtained by other
laboratories. Mangiarua and associates (1985) did not observe vascular hypertrophy in the

normotensive abdominal aortae of rats with aortic coarctation. Moreover, Bevan and
colleagues (1976) did not observe changes in wall thickness of normotensive saphenous

arteries of coarctated rabbits.
The production of animals genetically susceptible to the occurrence of spontaneous

hypertension has been achieved in rats (Smirk and Hall, 1958; Okamoto and Aoki, 1963 and

rabbits (Alexander et al, 1954). The strain developed by Okamoto and Aoki is referred to
as the "spontaneously hypertensive rat" (SHR). Okamoto and Aoki mated a hypertensive
3
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male Wistar rat (150 - 175 mmHg) with a female Wistar rat having mildly elevated blood

pressure (130 - 140 mmHg). Successive generations were achieved by mating siblings who
had high blood pressure persisting for at least one month.

With the spontaneously

hypertensive rat strain, researchers have observed a rise in blood pressure with age (Okamoto

and Aoki, 1963), cardiac hypertrophy (Yamabe and Lovenberg, 1974; Fischer, 1976), medial

hypertrophy in conductance (Owens, 1985) and resistance vessels (Warshaw et al., 1979; Lee
et al., 1983), and an increase in aortic connective tissue content (Yamabe and Lovenberg,

1974; Fischer, 1976). This animal model is possibly the closest experimental model to
essential hypertension in man.

Since the initial observations of hypertension, it has become clear that an outstanding

characteristic of essential hypertension is medial vascular hypertrophy. This term refers to
an increase in the thickness of the medial layer of vessels of hypertensive subjects as

compared with vessels of normotensive subjects. Medial vascular hypertrophy occurs in
arteries of all sizes ranging from conductance to resistance vessels in subjects with essential

and experimentally-induced hypertension.

In conductance vessels the hypertrophy is

predominately due to an increase in cell size, while in resistance vessels hypertrophy occurs
primarily through an increase in cell number (Mulvany et al., 1985).

Medial hypertrophy was described by Johnson in 1868 and later confirmed by Ewald
in 1877 (Folkow, 1982). Furuyama (1962) noted medial hypertrophy in the superior

mesenteric artery and the renal artery from patients with primary hypertension. Medial

hypertrophy has been observed in the caudal artery of rats with DOC/salt hypertension

(Friedman et al., 1971) and in the thoracic aorta of renal hypertensive rats (Wolinsky, 1970;
4

Wiener et al. 1977) and rats with aortic coarctation-induced hypertension (Olivetti et al.

1980). Warshaw et al. (1979) and Lee et al. (1983) found an increase in medial thickness of

large and small mesenteric resistance arteries from SHR.

In larger conductance vessels, medial vascular hypertrophy is characterized by
cellular hypertrophy and an increase in the content of specific macromolecules. Direct

chemical analysis of aortae of hypertensive animals as compared to normotensive animals

has revealed an increase in the content of DNA, protein, collagen, and elastin (Wolinsky,
1972; Yamabe and Lovenberg, 1974; Fischer, 1976; Foidart et al., 1978; Mangiarua et al.,
1981; Mangiarua et al., 1982). Smooth muscle cell hypertrophy occurs predominantly in

conductance vessels like the aorta and is commonly associated with an increase in the
incidence of polyploidy. Polyploid cells have a chromosome number that is a multiple of
For instance, Olivetti et al. (1980) have

the normal complement of chromosomes.

demonstrated that aortic coarctation-induced hypertension in male Wistar rats is

characterized by a 54% increase in vessel wall hypertrophy that can be accounted for by

smooth muscle cell hypertrophy. In this model, the volume of the thoracic aorta occupied
by smooth muscle cells increased by 57% and the mean smooth muscle cell volume

increased 55%. There was no change in the number of smooth muscle cells and collagen
content rose 136% (Olivetti et al., 1980). In a separate study, Owens et al. (1981) found an

increased average smooth muscle cell size with increased frequency of polyploidy in SHR

aortae compared to normotensive Wistar-Kyoto (WKY) rats. There was no change in

smooth muscle cell number suggesting that the increase in smooth muscle cell mass could

be accounted for by cellular hypertrophy rather than hyperplasia. These results were further
5
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substantiated using a different model of experimentally-induced hypertension. The thoracic
aortae of rats made hypertensive by the Goldblatt 2 kidney-1 clip method were found to have

a 40% increase in smooth muscle mass with a greater frequency of polyploid cells as

compared to sham-operated controls (Owens and Schwartz, 1983). In addition, the vascular
hypertrophy in this animal model occurred in association with smooth muscle cell
hypertrophy rather than hyperplasia as there was no change in smooth muscle cell number.
There is evidence that has been interpreted as suggesting that hyperplasia may also

occur in conductance vessels. Bevan et al. (1976) found an increase in DNA content and 3Hthymidine incorporation in the aortae of rabbits with hypertension induced by aortic

coarctation. These researchers correlated the increased DNA content to an increase in cell
number based on the assumption that smooth muscle cells remain diploid; however, cell
number was not measured in this study. It is possible that Bevan's results could be explained
by hypertrophy of polyploid cells rather than hyperplasia, if rabbits with aortic coarctation-

induced hypertension respond similarly to rats made hypertensive by the experimental

manipulations described above.
Although the precise mechanisms controlling vascular hypertrophy and the

pathogenesis of hypertension have not been elucidated, at least two feasible hypotheses have
been promulgated. Folkow's original hypothesis suggests that intermittent rises in blood

pressure are met by structural adaptations of the vasculature, such as medial hypertrophy, in
order to normalize the increase in vessel wall stress resulting from increases in intravascular
pressure. Folkow hypothesized that as the vessels hypertrophy the increase in smooth
muscle mass encroaches upon the lumen of the vessels thereby reducing the radius of the
6

vessel and further increasing intravascular pressure. A cycle would occur with increases in
pressure leading to further hypertrophy. Once established, Folkow (1978) believed vascular
hypertrophy could maintain a chronic elevation of blood pressure. An alternative hypothesis

outlined by Lever provides for the role of trophic factors in initiating medial vascular
hypertrophy which in turn would lead to an increase in blood pressure, further promoting

medial hypertrophy and hence maintenance of hypertension (Lever et al., 1992). One such
candidate trophic factor is angiotensin II (All).
All, an endogenous vasoconstrictor, is involved in normal blood pressure regulation

(Sealey and Laragh, 1995). In response to a reduction in blood pressure which is translated

into reduced renal arterial pressure, the kidneys secrete renin. Renin is an enzyme that

cleaves its substrate, angiotensinogen, to release angiotensin I (Al). Al is then converted to
All by angiotensin converting enzyme, located predominately in the lung vasculature. All

raises blood pressure by both direct and indirect mechanisms.

Directly, All causes

vasoconstriction of vascular smooth muscle cells. Indirectly, All plays a role in sodium and
water balance to expand plasma volume and subsequently raise blood pressure. All
stimulates the synthesis and secretion of aldosterone, a mineralocorticoid that stimulates

sodium and water reabsorption by renal tubules. All also exerts a negative feedback effect
on renin synthesis and secretion by the kidneys. Under normal homeostatic conditions, All

potently regulates blood pressure.
All binds to a specific plasma membrane receptor in order to elicit cellular responses.

Based on pharmacological characteristics, three receptors have been identified for AIL ATb

AT2, and AT3 (Harris and Inagami, 1995). While the signal transduction mechanisms for the
7
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AT2 and AT3 receptors have not yet been determined, there is a wealth of information
available for the secondary signaling events mediated by the AT] receptor. The AT! receptor
is coupled to a G-protein. All binding to this receptor activates a G-protein, which in turn

activates phospholipase C (Duff et al.,

1995).

Phospholipase C hydrolyses

phosphatidylinositol bisphosphate to yield diacylglycerol (Griendling et al., 1986) and
inositol trisphosphate. Inositol triphosphate binds to ligand-operated calcium channels in the

endoplasmic reticulum to promote an initial, rapid rise in cytosolic calcium (Alexander et
al., 1985). This is followed by a plateau phase of elevated calcium levels which appears to
be dependent upon the influx of extracellular calcium (Brock et al., 1985). Calcium can

initiate cellular events by binding to calcium-binding proteins that function as regulators of
cell function. The most ubiquitously distributed of these proteins is calmodulin. Calcium
calmodulin complexes modulate the activity of a variety of cellular proteins including
enzymes and membrane transport proteins to promote specific cellular activities (Head,

1992; O’Neil and DeGrado, 1990). The second product of phosphatidylinositol diphosphate

hydrolysis, diacylglycerol, remains associated with the plasma membrane to promote the
association of protein kinase C (PKC) with the inner surface of the plasma membrane

(Andrea and Walsh, 1992) where it is activated. Activated PKC elicits a cellular response
by promoting the phosphorylation of target proteins that mediate specific cell functions.

Multiple isoforms of PKC exist. The isoforms can be grouped into three broad categories
based upon their substrate specificity, structure, and activation requirements (Williams,

1995; Newton, 1995). The conventional PKCs (a, pb pn, and y) are calcium-dependent and

require DAG and membrane phospholipid for activation. The novel PKCs (6, e, 0, p, and
8

T|) are calcium-independent and require DAG and membrane phospholipid for activation.

The atypical PKCs (£, X, and i) are calcium-independent and do not require DAG or

membrane phospholipid for activation. Several isoforms of PKC have been identified in

vascular smooth muscle including, a, p, e, and £ (Andrea and Walsh, 1992).

Pathologically, All has been implicated in the development of vascular hypertrophy
associated with hypertension. This evidence stems from animal studies using captopril, an
angiotensin-converting enzyme inhibitor routinely used to reduce blood pressure in

hypertensive patients and from studies involving the chronic infusion of subpressor doses
of All.

In an experiment where antihypertensive drugs working through different

mechanisms were evaluated according to their efficiency in reducing medial hypertrophy,
only captopril was able to reduce the degree of vascular hypertrophy to an extent greater than

that predicted by its blood pressure-lowering effect (Owens, 1987). Captopril reduced the
tetraploidy, volume, and content of smooth muscle cells in the thoracic aortae of SHR. In
another study, All infusion was shown to promote vascular hypertrophy in normotensive
Sprague Dawley rats even when hydralazine, a blood pressure lowering agent, was given to

prevent the All-induced rise in blood pressure (Griffin et al., 1991). These data suggest that
All is able to promote vascular hypertrophy by a mechanism that is unrelated to increased

wall stress resulting from elevated blood pressure.
In vitro studies with cultured cells support the hypothesis that All has a direct trophic
effect on vascular smooth muscle. All has been shown to cause an increase in cell volume

(Geisterfer et al., 1988), protein synthesis (Berk et al., 1989), and DNA synthesis (Mangiarua

and McCumbee, 1990) relative to unstimulated cells. Similarly, All has been shown to
9
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stimulate the synthesis of extracellular matrix proteins (Scott-Burden et al., 1990; Kato et al.,
1991) and the transport of amino acids (McCumbee et al., 1996) by cultured vascular smooth

muscle cells.
In that All induces a number of growth promoting activities, it follows that All

stimulation of vascular smooth muscle cells will increase cellular demands for metabolic

energy.

Hypothetically, All could help the cells in meeting this requirement by

simultaneously stimulating glucose transport into those cells while promoting cellular
hypertrophy.

Glucose is a major energy substrate utilized by mammalian cells. The cell membrane

is impermeable to glucose. Glucose entry into the cell is made possible by a family of
structurally related facilitative glucose transporter proteins that are expressed in a tissue

specific manner (reviewed by Mueckler, 1994; Bell et al, 1990; Baldwin, 1993). The GLUT
1 transporter protein and/or message has been found in cells of blood-tissue barriers (Kalari
et al., 1988; Kasanicki et al., 1987; Pardridge et al., 1990; Tai et al., 1990) including vascular

endothelial and smooth muscle cells (Kaiser et al, 1993) and in all cell lines (Bell et al, 1990;

Mueckler, 1994). The GLUT 2 transporter protein is abundant in liver, pancreatic beta cells,
kidney, and the small intestine (Hacker et al., 1991; Thorens et al., 1988; Thorens et al.,

1990). The GLUT 3 transporter protein is abundant in the brain (Maher et al., 1992;

Nagamatsu et al., 1992). The GLUT 4 transporter protein is found primarily in insulin
sensitive tissues, such as skeletal muscle, heart and adipose tissue (Birnbaum, 1989; Charron

et al., 1989; Fukumoto et al., 1989; James et al., 1989; Kaestner et al., 1989). The GLUT 5

transporter protein is abundant in the small intestine and recent evidence suggests that this
10
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transporter is primarily a fructose transporter (Burant et al., 1992; Davidson et al., 1992).

GLUT 6 is a pseudogene that does not encode a functional protein (Kayano et al., 1990).

The GLUT 7 transporter protein is located in the endoplasmic reticulum of hepatocytes and
releases free glucose into the cytoplasm of these cells which, in turn, may exit the cells via

a different glucose transporter (Waddell et al., 1991). Transporter proteins contain from 492

to 524 amino acids and there is 39-65% identity and 50-76% similarity among amino acid
sequences of the transporter isoforms (Bell et al., 1990). The region of amino acids that is
most different among the transporter isoforms is located in the carboxyl terminus (Bell et al.,

1990). The carboxyl terminal region is routinely used to generate antibodies specific for the
individual transporters.
GLUT 1 is the best characterized of the glucose transporters. It has been purified

from human erythrocytes and cloned from human hepatoma cells and rat brain (Mueckler,
1994). This transporter is believed to be responsible for basal glucose transport (Mueckler,
1990). Stimulation of glucose transport activity in many types of cells has been attributed

to regulation of GLUT 1 by changes in transcription, translation, degradation, translocation
and intrinsic activity. GLUT 1 expression has been shown to be regulated by glycemia
(Haspel et al., 1986; Kaiser et al., 1993), growth factors (Hiraki et al., 1988; Rollins et al.,
1988), oncogene transformation (Flier et al., 1987), insulin (DeHerreros and Birnbaum,
1989), and angiotensin II (Low et al., 1992). A decrease in GLUT 1 degradation has been

observed with glucose deprivation (Haspel et al., 1986; Ortiz et al., 1992). Translocation of
GLUT 1 to the cell surface has been observed with glucose deprivation (Koska et al., 1991;
Greco-Perotto et al., 1992), and insulin stimulation (Gould et al., 1989). Regulation of
11

GLUT 1 intrinsic activity has been implied in several studies where an increase in glucose

transport occurs with a reduction in Km value (Clancy et al., 1991; Harrison et al., 1991) and

where other regulatory mechanisms such as translocation or expression cannot fully account
for the increase in glucose transport activity (Koska et al., 1991; and Kitzman et al., 1993).

For instance, Clancy et al. (1991) observed a maximal 7-fold increase in glucose uptake by

3T3-L1 adipocytes using the protein synthesis inhibitors, anisomycin and cycloheximide.

The anisomycin effect occurred with a reduction in Km. The effect of both protein synthesis
inhibitors on glucose transport did not involve an increase in GLUT 1 or GLUT 4 proteins

in the plasma membrane of the cells suggesting that the intrinsic activity of the glucose

transporters is altered in response to this treatment. Further, Harrison et al. (1991) detected
an increase in glucose transport in 3T3-L1 fibroblasts in response to cadmium through a
mechanism involving a change in glucose transporter intrinsic activity. Cadmium treatment
increased glucose transport into the cells 5- to 6-fold with a reduction in Km and no change

in cell surface GLUT 1 protein. In summary, regulation of glucose transport activity through
the GLUT 1 transporter appears to vary with the type of cell and the nature of the stimulus.

The role of glucose deprivation in the regulation of the GLUT 1 transporter has been

extensively investigated. Glucose deprivation has been shown to stimulate glucose transport
through several different mechanisms such as increased GLUT 1 expression (Kletzien and

Perdue, 1975; Kumagai et al., 1995; Van Putten and Krans 1985; Yamada et al., 1983),

decreased GLUT 1 degradation (Haspel et al., 1986; Ortiz et al., 1992; and Yamada et al.,
1983), increased GLUT 1 mRNA (Koivisto et al., 1991; Kumagai et al., 1995; Walker et al.,
1988; and Walker et al., 1989), and enrichment of GLUT 1 at the cell surface through
12
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possible control of cellular trafficking (Koska et al., 1991; and Greco-Perotto et al., 1992).
Intrinsic regulation of the transporter by glucose deprivation has also been implicated

(Kitzman et al., 1993; Koska et al., 1991).

Recently, Kaiser and associates (1993)

demonstrated that low glucose stimulated transport in cultured vascular smooth muscle cells
by an increase in GLUT 1 and a change in Vmax with no apparent changes in Km or GLUT

1 mRNA abundance.

Low et al. (1992) have demonstrated that All stimulates glucose transport in cultured
VSM cells 1) through a rapid response that is protein synthesis-independent and 2) through
a more prolonged response that involves an increase in GLUT 1 mRNA synthesis without

a change in stability of the message. The mechanism underlying the rapid response was not

explored by these researchers and could be explained by an increase in intrinsic activity
and/or translocation of GLUT 1. There has not been an attempt to explore the second

messenger events associated with All binding and the resultant increase in glucose transport

nor has the effect of the glycemic state on All-stimulated glucose uptake been investigated.
The purpose of this research was to further explore the role of All in the stimulation

of glucose transport in cultured vascular smooth muscle cells. Specific emphasis was placed
on the role of PKC activation and extracellular calcium in mediating the effects of AIL In
addition, the effects of All on the expression of the GLUT 1 transporter were investigated

as was the role of the cellular glycemic state on All stimulation of glucose transport.

13

METHODS

CELL CULTURE

Vascular smooth muscle (VSM) cells were isolated from rat thoracic aortae via

enzymatic digestion as described by Gunther et al. (1982). Briefly, thoracic aortae were

excised from six anesthetized (ketamine HC1 and xylazine, 45:5 mg/kg) 275-350 gram male
Sprague-Dawley rats via midline incision under aseptic conditions. The aortae were rinsed

in sterile Isolation Buffer [Mg2+-free Hank's Balanced Salt Solution (BBSS) containing 0.2
mM CaCl2, 15 mM HEPES, and 14 mM glucose and adjusted to pH 7.4] and cut

longitudinally. Endothelial cells were removed by gentle rubbing with the back of a curved

pair of tweezers. The tunica media was separated from the tunica adventitia with the aid of
a dissecting scope, cut into small pieces, and then subjected to enzymatic digestion for 30-40

minutes at 37°C using type II collagenase (700 U/ml), type II elastase (160 U/ml), type II
DNase (300 U/ml), and a soybean trypsin inhibitor (1 mg/ml) suspended in 6 ml of Isolation

Buffer in a siliconized flask. The resultant digest was then aspirated into and out of a

siliconized, glass Pasteur pipet 20 times. The cell suspension was passed through a sterile
nylon mesh filter and the remaining pieces were subjected to digestion for 10 minutes in 2

ml of fresh enzyme solution. The cells were recovered by centrifugation, rinsed once with

DMEM, resuspended in 4 ml of serum-free DMEM and placed into two T-25 tissue culture
flasks. Two hours later, 8 ml of DMEM containing 10% newborn calf serum were added to

each flask. The medium was changed again on the following day and twice a week
thereafter.
14

VSM cells were grown in Dulbecco's Modified Eagle Medium (DMEM) [with 25
mM HEPES and 25 mM glucose, pH 7.4] that was supplemented with 10% heat-inactivated
newborn calf serum and penicillin (100 U/ml) / streptomycin (100 U/ml) at 37°C in a
humidified atmosphere of 5% CO2 and air. The medium was changed twice weekly. For

passaging, cells were detached from the flasks with 0.05% trypsin/ 0.53 mM EDTA in
HBSS. Cells from passages 3-10 were used for the experiments.

|3H]-2-DEOXYGLUCOSE TRANSPORT MEASUREMENTS

Glucose transport was assayed by measuring the uptake of radiolabeled 2-

deoxyglucose (2-DG). This assay is based on the principle that 2-DG is transported by the
same carrier as D-glucose and then phosphorylated to 2-deoxyglucose-6-phosphate (2-DGP)
by hexokinase (Wick et al., 1957). The 2-DGP does not exit the cell nor is it metabolized

further.
Cultured VSM cells were seeded at a density of 4.5 - 5 x 105 cells/well in 6-well

culture plates. The cells were grown in DMEM containing 10% heat-inactivated newborn

calf serum for 7-9 days. Forty-eight hours prior to the start of an experiment, the medium
was changed to DMEM containing 0.4% heat-inactivated newborn calf serum to ensure

quiescence. At the beginning of a given experiment, the low serum medium was replaced

with fresh medium containing specific agents. The cells were exposed to these agents for
various time periods.

To assess glucose transport, the low serum medium was removed and the cells were
rinsed twice with and then equilibrated for 30 minutes in a Kreb's Ringer Phosphate buffer
15

(136 mM NaCl, 4.7 mM KC1, 1.25 mM CaCl2, 1.25 mM MgSO4, 10 mM Na2HPO4, and 10

mM NaH2PO4, pH 7.4). The specific agents added at the start of the experiment or an
equivalent volume of carrier were replenished at the beginning of the equilibration period.
Then 50 jj\ of a solution containing unlabeled 2-deoxyglucose (20 //M) and [3H]-2deoxyglucose (0.5 //Ci) were added to each well for 20 minutes. During this time glucose

transport is linear (Appendix A).

To terminate the experiment, the radioactive incubation

buffer was rapidly aspirated from the wells and the cells were rinsed twice with ice-cold

phosphate-buffered saline (20 mM Na2HPO4/ NaH2PO4 and 140 mM NaCl, pH 7.4). The
cells from each well were harvested using trypsin/ EDTA in HBSS, dissolved in Universol

ES (ICN Biochemicals, Irvine, CA), and radioactivity levels detected using a Beckman LS
5801 liquid scintillation counter. In several different experiments, nonspecific transport was

assessed by adding 15 //M cytochalasin B to half of the wells in each treatment group 20

minutes into the incubation period. Cytochalasin B is a fungal metabolite used widely to
inhibit glucose transporter activity (Czech et al., 1973; Kletzien and Perdue, 1973). Glucose
uptake in the presence of cytochalasin B occurs through nonspecific means. Nonspecific

transport accounted for less than 7% of total glucose transport per treatment group (Appendix

B). In the studies to determine the level of nonspecific transport, each treatment group

consisted of either three or six samples incubated in the presence of cytochalasin B and either
three or six samples incubated in the absence of cytochalasin B. In the remainder of the
experiments, each treatment group consisted of six samples. In each plate, there was a well

representing each experimental treatment. The results were expressed as pmoles of glucose

transported/ 106 cells. Cells were removed from the wells using trypsin/ EDTA and were
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counted using a hemacytometer. Each experiment was repeated a minimum of three times

using cells derived from different primary isolations. The experiments presented are

representative experiments.

PEPTIDE SYNTHESIS AND ANTIBODY PRODUCTION
A peptide corresponding to the last 15 amino acids (TPEELFHPLGADSQV, see

Appendix C for an abbreviation key) of the carboxyl-terminus of the GLUT 1 transporter
was synthesized by 9-fluorenylmethoxycarbonyl (Fmoc) chemistry (Fields and Noble, 1990)

using the “standard scale” protocol of the Applied Biosystems (ABI) Model 431A Peptide

Synthesizer. Specific Fmoc amino acids were sequentially added from cartridges, each
containing 1 mmole of derivatized amino acid, to 0.1 mmole of ABI 8-branch Multiple
Antigenic Peptide (MAP) resin. With this procedure, several identical peptides can be

synthesized onto the branched lysine residues of the MAP resin. Once cleaved from the
resin, the antigen used to immunize rabbits will be a complex of numerous peptides attached

to lysine. This product is large enough to be completely immunogenic making a carrier
protein unnecessary and eliminating antibodies generated against a carrier.
Following synthesis, the immunogenic product was cleaved from the resin and

isolated as follows.

The newly synthesized peptide-resin mixture was washed with

di chloromethane and dried under high vacuum for 30 to 60 minutes prior to cleaving the
synthesized peptides from the resin. The dried peptide-resin was placed into a flask and

cooled in an ice bath. The cleavage solution [0.25 ml 1,2-ethanedithiol, 0.25 ml deionized
and distilled water, plus 9.5 ml trifluoroacetic acid] was cooled using an ice bath and then
17
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added to the cooled peptide-resin to give a final volume of 10 ml per 0.1-1.5 g of peptideresin. The flask was removed from the ice bath and the contents were allowed to warm to

room temperature. The flask was stoppered and the peptide-resin was exposed to the
cleavage solution for 1.5 hours with stirring. At the end of the cleavage period, the peptide

was isolated from the resin using vacuum filtration through a medium-porosity, fritted glass
funnel. The peptide remained in the filtrate while the resin was too large to be filtered. In
order to isolate the peptide from the filtrate, the filtrate was concentrated on a rotary

evaporator to a volume of approximately 1 to 2 ml. Approximately 50 ml of cold ether was
added to the concentrated filtrate to precipitate the peptide. The peptide was collected by
filtering the mixture through a fme-porosity, fritted glass funnel. The precipitate was dried
in a desiccator. After drying, the peptide was dissolved in a few ml of deionized/ distilled

water and lyophilized. The yield of each of two cleaved and isolated batches of peptide was
25.8 mg and 51 mg of material. This represents approximately 50% of the theoretically

possible yield.
The multiple peptide antigen complex was emulsified in 50% (v/v) Hunter’s Titer

Max™. Each rabbit was relaxed prior to injection using approximately 0.75 cc acepromazine

administered intramuscularly in the hindlimb. The injection sites were shaved and cleaned
with alcohol to reduce the presence of material that could cause infection. Two intradermal
injections (0.05 cc/ site) of emulsified peptide were administered on the back of each rabbit.

Each rabbit received approximately 1.5 to 2 mg of peptide.

Blood samples were taken

periodically to assess the level of serum antibodies. To obtain blood samples, the rabbit was

relaxed using 0.75 cc acepromazine. An ear was shaved, swabbed with alcohol, and blood
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withdrawn from the central ear artery. The sample size did not exceed one percent of the

body weight of the animal. The animals received five booster doses of peptide in Hunter’s
Titer Max™. The serum antibody titer obtained using Hunter’s Titer Max™ as adjuvant

was never greater than 1:10. Therefore, the protocol was adjusted to employ Freund's
complete adjuvant (FCA). FCA is the adjuvant widely used to generate glucose transporter

antibodies. The Titer Max™ was used initially to approach the animals with a procedure
offering fewer side effects than FCA. The peptide was emulsified in 50% (v/v) FCA and
injected intradermally (0.05 cc/ site) into five shaved, alcohol swabbed sites on the back of
each rabbit. Each animal received approximately 2 mg of peptide. Five booster doses of

antigen, approximately 1 mg/ animal, in Freund's incomplete adjuvant were administered at
30 day intervals and two weeks prior to serum collection for antibody titer assessment. Prior

to Freund’s complete and incomplete adjuvant administration and blood collection the
animals received 0.75 cc acepromazine. The health and comfort of the rabbits was attended

to by a veterinarian.

ELISA
An enzyme-linked immunosorbent assay (ELISA) was used to determine the titer of
peptide-specific antibodies in immunized rabbit sera. The assay was based on a modification

of the procedure described by Kennett (1980). The GLUT 1 peptide (antigen) was suspended
in deionized/ distilled water at a final concentration of 10 //g/ ml. Wells of polystyrene micro
titer plates were coated with 100 //I of peptide solution per well during an overnight
incubation at 4°C. The remaining incubations were carried out at room temperature with
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shaking using a rocking platform. The remaining protein-binding sites were blocked using

100 //I of 10 mM dibasic sodium phosphate with 0.9% NaCl and 1% bovine serum albumin
(BSA) per well. The blocking solution was removed by inverting the plate and the wells
were washed five times with approximately 200 //I per well of phosphate-buffered saline

(PBS, 10 mM Na2HPO4 /NaH2PO4 and 140 mM NaCl, pH 7.2). Next, antiserum (100 /d,
primary antibody), diluted 1:100 with PBS containing 1% BSA, was added to each peptide-

coated well and allowed to bind for two hours at room temperature. Wells were washed five
times with approximately 200 //I per well PBS to remove unbound primary antibody. One
hundred //I of horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG (secondary

antibody) diluted 1:1000 in PBS with 1% BSA were added to each well and incubation

continued for two hours at room temperature.

Wells were washed five times with

approximately 200 //I per well PBS to remove unbound secondary antibody. The presence
of the bound secondary antibody and therefore the interaction of primary antibody with
antigen was assessed by measuring HRP activity of the conjugated secondary antibody. HRP

activity was assessed by adding to each well 200 //I of a solution containing 1 mg/ml Ophenylenediamine, 1% hydrogen peroxide, and 0.1 M sodium citrate (pH 4.5). The presence

of HRP is indicated by a change in the color of the assay solution from clear to yellow which

takes approximately 10-15 minutes. The color intensity was then determined by measuring
the absorbance of the solution at 450 nm using a Vmax Kinetic Microplate Reader
(Molecular Devices, Menlo Park, CA). The intensity values were recorded as optical density
measurements. Nonspecific antibody-binding was determined using a 1:100 dilution of
primary antibody in the absence of the peptide antigen. Optical density measurements
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obtained for each experimental group were corrected for nonspecific antibody-binding.

MEMBRANE ISOLATION

Cells were seeded at a density of 10-12 x 106 cells/ flask in T-225 tissue culture flasks

and grown in DMEM containing 10% heat-inactivated newborn calf serum for 7-9 days.
Forty-eight hours prior to the start of the experiment, the medium was changed to DMEM
containing 0.4% heat-inactivated newborn calf serum. At the start of the experiment, the low

serum medium was removed and the cells were rinsed twice with 0.9% NaCl. The medium
was replaced with medium containing either 2.5 mM glucose or 25 mM glucose and the

incubation was allowed to proceed for an additional 24 hours. Six hours prior to the end of

the incubation period, All (final concentration 100 nM) or an equivalent volume of vehicle
(0.9% NaCl) was added to the culture medium. At the end of the experiment, the medium

was removed and the cells were rinsed twice with ice-cold 0.9% NaCl. Medium glucose

concentration was measured at the beginning and at the end of the 24 hour incubation period

using an enzymatic-colorimetric glucose assay (Stanbio Laborator}7, Inc., San Antonio, TX).
During the course of this assay, the glucose present in the medium is oxidized by glucose
oxidase to form gluconic acid and hydrogen peroxide. The hydrogen peroxide then reacts

with 4-aminophenazone in the presence of peroxidase to yield a red-violet quinone complex.
The absorbance of the resulting colored product was measured at 500 nm within 60 minutes

using a Beckman DU-8 spectrophotometer. The concentration of glucose in the sample
tested was calculated using the following formula:
mg/ dl glucose = [absorbance of unknown

absorbance of standard] x the concentration of the standard (100 mg/ dl).
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Crude membranes were isolated by the method of Klip et al. (1987) with
modifications. The cell monolayer was removed by scraping, centrifuged at 3,000 rpm for

10 minutes at 4°C in a Beckman GS-6R refrigerated centrifuge, resuspended in

approximately 1 ml of Buffer A [10 mM NaHCO3, 250 mM sucrose, 5 mM NaN3, pH 7.0]
plus 5 mM phenylmethylsulfonylfluoride (PMSF) and 10 /7 g/ ml pepstatin A, and disrupted

with several brief bursts of an Ultrasonic Processor (Cole-Parmer Instrument Co.). The
disrupted cells were centrifuged at 1,200 xg in a Sorvall RC-5B refrigerated centrifuge for

10 minutes at 4°C. The supernatant fraction was saved and the pellet resuspended in Buffer

A, resonicated as above, and centrifuged at 1,200 xg for 10 minutes at 4°C. Both 1,200 xg
supernatant fractions were pooled and centrifuged at 9,000 xg for 10 minutes at 4°C. The

pellet was discarded and the supernatant was collected and centrifuged at 190,000 xg for 60

minutes at 4°C using a SW41 rotor in a Beckman Model L5-65 Ultracentrifuge. The
resulting pellet contained the crude membranes which were resuspended in Buffer B [10 mM

NaHCO3, 5 mM NaN3, pH 7.0] plus 5 mM PMSF and 10 //g/ ml pepstatin A. Protein
determinations were made using the bicinchoninic acid assay (Pierce, Rockford, IL).

WESTERN BLOT ANALYSIS

Fifty microgram quantities of crude membrane proteins from each experimental
group were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis

(SDS PAGE) according to the method of Laemmli (Laemmli, 1970) and electrophoretically

transferred to nitrocellulose membranes. Briefly, the proteins were separated through 15%
polyacrylamide separating gels at 60 volts applied overnight using a PROTEAN® II xi Cell
22
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Apparatus (BIO-RAD, Richmond, CA). The proteins were then transferred to nitrocellulose
membranes using a Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell (BIO-RAD).
Each gel was removed from the gel apparatus and allowed to equilibrate in transfer buffer

(48 mM Trizma base, 39 mM glycine, 20 % methanol, 0.00375% SDS, pH 9.2; Bjerrum and
Schafer-Nielsen, 1986) for approximately 30 minutes with shaking using a rocking platform.

Enough transfer buffer was added to a glass dish containing the gel to completely submerge

the gel. After 10 minutes, the transfer buffer was replaced with fresh buffer and the
incubation continued. The nitrocellulose membrane was cut to the dimensions of the gel and

soaked in transfer buffer for at least 30 minutes with shaking. Four pieces of thick filter
paper were cut to the dimensions of the gel and soaked in transfer buffer for approximately
15 minutes with shaking. Following soaking in transfer buffer, two pieces of filter paper

were placed upon the platinum anode plate followed sequentially by the nitrocellulose
membrane, the equilibrated gel, two final pieces of filter paper, and the platinum cathode

plate. Care was taken to remove all air bubbles between the layers of filter paper, gel, and
membrane to ensure an uninterrupted transfer. The transfer was accomplished using a
current of 23 V applied for 30 minutes.
Specific proteins were detected on the nitrocellulose membranes using the procedure
described by Green et al. (1992). The nitrocellulose membranes were blocked for one hour

with shaking using enough Tris-saline [10 mM Tris, 150 mM NaCl, 0.2 mM EDTA, pH 8]
plus 0.05% Tween 20 and 5% (w/v) nonfat dried milk to cover the membrane. At the end

of the one hour incubation period, the blocking buffer was replaced with fresh buffer.
Polyclonal antibodies (primary antibodies) against synthetically prepared GLUT 1 carboxyl23

terminus were added to this buffer to give a dilution of 1:1,000, unless otherwise noted, and

incubation proceeded for 2.5 hours with shaking. After thorough washing in enough Tris
saline with 0.05 % Tween 20 (Tween-Tris-saline) to sufficiently cover the membrane, the
nitrocellulose membranes were exposed to alkaline phosphatase-conjugated goat anti-rabbit
IgG (secondary antibody) diluted 1:1000 with 5% (w/v) nonfat dried milk in Tween-Tris-

saline for 1.5 hours, and washed twice in Tween-Tris-saline followed by a final wash in Tris
saline. The presence of alkaline phosphatase was assessed by exposing the membranes to

a color developing solution (10 ml of 1 M Tris, pH 9.5; 5 ml of 2 M NaCl; 0.5 ml of 1 M
MgCl2; 84.5 ml deionized and distilled water; 0.4 ml of 75 mg/ ml nitroblue tetrazolium
dissolved in 70% N,N-di methyl formamide; and 0.3 ml of 50 mg/ ml 5-bromo-4-chloro-3-

indolyl phosphate dissolved in 100% N,N-dimethylformamide) for approximately 30
minutes with shaking. The 5-bromo-4-chloro-3-indolyl phosphate served as substrate. The

inclusion of nitroblue tetrazolium in the reaction mixture allowed for visualization of the

presence of alkaline phosphatase. The result of the alkaline phosphatase reaction was a
purple precipitate (McGadey, 1970). The color development reaction was terminated by

removing the color developing solution and rinsing the membranes with deionized and

distilled water. The membranes were placed between two pieces of filter paper to dry. The
membranes were analyzed using a scanning densitometer (Molecular Dynamics) to

determine relative amounts of the GLUT 1 protein. The level of the GLUT 1 protein was

expressed as arbitrary units.
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MATERIALS
[3H]-2-deoxyglucose (26.2 Ci/mmol) was purchased from NEN/ DuPont (Boston,
MA). DMEM, newborn calf serum, trypsin/ EDTA, penicillin/streptomycin, amino acids,

and vitamins were purchased from Gibco BRL (Grand Island, NY). Other chemicals were
obtained from Sigma Chemical Company (St. Louis, MO) or Fisher Scientific (Pittsburgh,
PA).
Calcium-free and glucose-free media were prepared based on the formulation of
DMEM #12430 (Appendix D) supplied by Gibco BRL (Grand Island, NY). The osmolality

of these solutions was adjusted to that of the standard DMEM formulation by the addition
of an appropriate quantity of NaCl. Gibco BRL-formulated solutions of amino acids and

vitamins were used to provide these components for the prepared media.

ANIMALS.
Male Sprague-Dawley rats were obtained from Hilltop Lab Animals, Scottdale, PA

and were housed in plastic cages with wood-chip bedding. Male New Zealand white rabbits

were obtained from Robinson Services, Inc., Winston-Salem, NC and were housed in
stainless steel rabbit cages. Both animal species were maintained in rooms having an
ambient temperature of 23 + 2 °C and a 12 hour light/ dark cycle for 5-7 days prior to use.

All animals had free access to food and tap water. Protocols involving animal use were
approved by the Institutional Animal Care and Use Committee.
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STATISTICAL ANALYSIS
Each type of experiment was repeated a minimum of three times using cells from

different cell lines. The individual experiments presented in the paper are representative
experiments. Statistical analyses were made using SuperANOVA™ software (Abacus
Concepts, Berkeley, CA). Significant differences among the means in an experiment were
determined by one-way analysis of variance followed by Newman-Keuls post hoc test or by

two-way analysis of variance where appropriate. Following two-way analysis of variance,

'’contrasts” (Abacus Concepts, Berkeley, CA) was used to make specific, preplanned
comparisons.
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RESULTS
To determine if All stimulated glucose transport in a time-dependent manner,
cultured VSM cells were exposed to 100 nM All for various time intervals. After one hour

of incubation, the rate of glucose transport in cells exposed to All was significantly greater
than the rate of transport in the corresponding control (Figure 1). The rate of transport
continued to rise with increasing time of exposure with the maximum All response being

observed between six and eight hours. The maximum rate of transport was maintained

through 20 hours, the longest time period for which a measurement was made.

To determine if the All effect on glucose transport was concentration-dependent,

VSM cells were exposed to various concentrations of All for six hours. VSM cells
responded to All at concentrations as low as 0.1 nM (Figure 2). The maximum response was

observed at 100 nM All.
To determine whether the All effect on glucose transport was mediated by the All
receptor, VSM cells were incubated with a 100 molar excess of saralasin, a competitive

inhibitor of All receptor binding. As shown in Figure 3, saralasin reduced All-stimulated
transport to a level not significantly different from that induced by saralasin alone. This data
suggests that All is binding to its receptor to stimulate glucose transport.
The long period of time required to elicit a maximal All effect on glucose transport

suggests that this response may require protein synthesis. To test this hypothesis, VSM cells

were incubated for six hours with and without All in the presence or absence of 10 //M
cycloheximide, an inhibitor of protein synthesis. Under these conditions, cycloheximide
27

Figure 1

Time course for All-stimulated glucose transport. Cultured vascular smooth

muscle cells were exposed to 100 nM All for 1, 2, 4, 6, 8, 16, and 20 hours. The All was
dissolved in deionized/ distilled water to make a stock solution of 1 mM (1 mg/ ml). The All

stock solution was diluted 1:100 with deionized/ distilled water and added as 25 //I aliquots

to the incubation medium to give a final concentration of 100 nM. Cells incubated with an
equivalent volume of diluent alone served as controls. Each point is the mean + SEM of six

replicates. Data are expressed as percent stimulation above control. At each time point, All

stimulated glucose transport was significantly (p
control.
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Figure 2

Dose response curve for stimulation of glucose transport by AIL Cultured

vascular smooth muscle cells were incubated for six hours with diluent, 0.1, 1, 10, 50, 100,

or 1000 nM AIL The stock solution of All (1 mg/ ml) was diluted with deionized/ distilled

water and added as 25 //I aliquots to the incubation medium to give the final concentrations
listed above. An equivalent volume of diluent was added to cells to serve as the control.
Results are expressed as pmoles of glucose transported/ 106 cells. Each point is the mean ±

SEM of six replicates. The control value was 616 + 22.9 pmoles / 106 cells. All-stimulated
glucose uptake was significantly (p

0.05) greater than that of the control for each

concentration of AIL
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Figure 3

The effect of saralasin on All-stimulated glucose transport. Cells were

incubated with diluent, 100 nM All, 10 //M saralasin (SARA), or 100 nM All + 10 nM
SARA for six hours. The SARA was dissolved in deionized/ distilled water to make a 1 mM

stock solution (1 mg/ ml). In order to achieve a final concentration of 10,000 nM, 25 //I of
the stock solution was added to the incubation medium of cells treated with SARA. The All

stock solution (1 mg/ ml) was diluted 1:100 and 25 //I was added to the incubation medium.
An equivalent volume of diluent was added to the incubation medium to serve as control.
Results are expressed as pmoles of glucose transported/ 106 cells. Bars represent the mean

and brackets the SEM of six determinations. *p
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reduced All-stimulated transport by 70% (Figure 4) suggesting that protein synthesis is

involved in All stimulation of glucose transport.
A specific protein that could be affected by All stimulation is the GLUT 1
transporter. Western blot analysis was utilized to assess this possibility. For these studies,

a polyclonal antibody was generated against the carboxyl terminus of the GLUT 1
transporter:

this region exhibits the lowest degree of homology among the glucose

transporter isoforms (Table 1; Bell et al., 1990). Subsequently, the specificity of this

antibody (3406 GLUT 1 Ab) was assessed by using an enzyme-linked immunosorbent assay

to compare the cross-reactivity of the 3406 GLUT 1 Ab with synthetic peptides
corresponding to the carboxyl termini of four different glucose transporter isoforms (GLUT
1, 2, 4, and 7). In addition, the degree of cross-reactivity of the synthetic peptides to a

second, commercially available, anti-GLUT 1 antibody was determined. With a 1:100

dilution, the 3406 GLUT 1 Ab reacted strongly with the GLUT 1 peptide and much less so

with the other GLUT peptides (Table 2). When the dilution of antibody was raised to
1:1,000, the optical density recordings for GLUT 2, 4, and 7 were less than the background

measurement (Appendix E). The data support the hypothesis that the 3406 GLUT 1 Ab is
specific for GLUT 1. Moreover, this study provided additional evidence that the GLUT 1
peptide synthesized in our hands was an appropriate antigen due to the intense reaction

observed with the commercially available anti-GLUT 1 antibody (East Acres Biologicals,
Southbridge, MA).

To further ensure that the 3406 GLUT 1 Ab recognized the GLUT 1 transporter, red
blood cell membranes were used as positive controls when VSM cell membranes were
34
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Figure 4

The effect of cycloheximide on All-stimulated glucose transport. Cultured

VSM cells were incubated with 10 //M cycloheximide (CHX) or vehicle in the presence of

100 nM All or vehicle for six hours. The cycloheximide was dissolved in deionized/
distilled water to prepare a stock solution with a concentration of 10 mM (2.8 mg/ ml). The

stock CHX solution was diluted 1:100 and 50 //I aliquots were added to the incubation
medium of cells receiving CHX to give a final concentration of 10 //M. The stock All

solution (1 mg/ ml) was diluted 1:100 and 25 //I aliquots were added to the incubation

medium of cells receiving All at a final concentration of 100 nM. Control cells received an
equivalent volume of diluent. Results are expressed as pmoles of glucose transported/ 106

cells. Bars represent the mean and brackets the SEM of six determinations. * p < 0.05 vs.
Control. + p

0.05 vs. All.
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CHX
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+
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Intracellular COOH-Terminal Domain
GLUT 1

KGRTFDEIAS ; GFRQGGASQSDK ; TPEELFHPLGADSQV

GLUT 2

KGKSFEEIAA ' EFQKKSGSAHRP ■ KAAVEMKFLGATETV

GLUT 3

RGRTFEDITR ; AFEGQAHGADRS } GKDGVMEMNSIEPAKETTTNV

GLUT 4

RGRTFDQISA ] AFHRTPSLLEQE

GLUT 5

KAKTFIEINQ | IFTKMNKVSEVY > PEKEELKELPPVTSEQ

Table 1

i VKPSTELEYLGPDEND

Comparison of the amino acid sequences of the intracellular carboxyl

termini of human glucose transporters (Bell, et al., 1990; see Appendix C for a key
to the amino acid abbreviations).
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Optical density measurements

Synthetic peptide

3406 GLUT 1 Ab

Commercial GLUT 1 Ab

GLUT 1

1.632

>3

GLUT 2

0.155

0.127

GLUT 4

0.027

0.021

GLUT 7

0.196

0.332

Table 2

Detection of cross-reactivity of 3406 GLUT 1 Ab with GLUT 1,2, 4, and 7

synthetic peptides. The antibody dilution was 1:100 and the optical density measurements
were corrected for background. The optical density measurements obtained for nonspecific
binding of the antibody in the absence of antigen served as the background measurement.

This measurement was subtracted from those measurements obtained for each of the
experimental groups. The corrected values are presented.
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subjected to western blot analysis (Figure 5). Red blood cell membranes are enriched in

GLUT 1 transporters (Carruthers, 1990). The 3406 GLUT 1 Ab recognized protein bands
from red blood cell membranes and smooth muscle cell membranes that correspond to

published molecular weights for the GLUT 1 transporter (Gorga et al., 1979; Kumagai et al.,

1994).
To assess the effects of All on the GLUT 1 transporter, membranes prepared from

VSM cells incubated with and without All were separated by polyacrylamide gel
electrophoresis, transferred to nitrocellulose membranes and then probed with the 3406
GLUT 1 Ab. There was a 5-fold increase in the level of immunoreactive GLUT 1 following

a six hour exposure to All (Figure 6). These results support the conclusion that All is
capable of altering the level of the GLUT 1 glucose transporter.
All elicits a response in target cells by increasing the concentration of free cytosolic

calcium and by activating protein kinase C (PKC) (Griendling et al., 1989). The role of PKC

activation in mediating All-stimulated glucose transport was assessed using phorbol esters.
In one experiment PKC was activated by a short-term (six hour) exposure of VSM cells to

50 nM phorbol-myristate-acetate (PMA) or 100 nM phorbol-dibutyrate (PDB) prior to

measuring glucose uptake. As shown in Figure 7, both PMA and PDB significantly
stimulated glucose transport under these conditions suggesting that PKC activation can
promote glucose transport. In another experiment, VSM cells were exposed to 1 //M PDB

for 48 hours in order to promote PKC downregulation. Subsequently, the cells were

stimulated with All for six hours and glucose transport was measured.

Under these

conditions, All was capable of fully stimulating glucose transport in the presence of PDB
39

Figure 5

Detection of the GLUT 1 transporter in smooth muscle and red blood cell

membranes using the prepared 3406 GLUT 1 Ab. Dilutions of 1:2,500 and 1:1,000 of the

antibody were used for analysis.
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Figure 6

The effect of All on GLUT 1 protein levels. VSM cells were incubated with

100 nM All or diluent for six hours. Crude membranes were isolated and subjected to

western blot analysis using a 1:1,000 dilution of the 3406 GLUT 1 antibody. The level of

immunoreactive GLUT 1 was assessed using densitometric analysis. The results are
expressed as arbitrary units.
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Figure 7

The effect of PKC stimulation with phorbol-12,13-dibutyrate (PDB) or

phorbol-12,14- myristate acetate (PMA) on glucose transport. Cells were incubated with 100

nM All, 100 nM PDB, 50 nM PMA, or diluent for six hours. The PDB was dissolved in
dimethylsulfoxide (DMSO) to prepare a stock solution of 10 mM (5mg/ 1 ml). The stock

solution was diluted 1:200 and then 1:9 with 0.9% NaCl and 50 /zl aliquots were added to

the incubation medium of cells treated with PDB to give a final concentration of 100 nM.
The cells treated with PDB alone also received 25 //I of 0.9% NaCl. The PMA was dissolved

in DMSO at a concentration of 10 mM (5mg/ 0.81 ml). This stock solution was diluted

1:200 and then 1:19 with 0.9% NaCl and 50 //I aliquots were added to the incubation
medium of cells treated with PMA to give a final concentration of 50 nM. The cells treated
with PMA alone also received 25 //I of 0.9% NaCl. The stock All solution (1 mg/ ml) was
diluted 1:100 with 0.9% NaCl and 25 //I was added to the incubation medium of cells

receiving All at a final concentration of 100 nM. The cells treated with AU alone also

received 50 //I of DMSO diluted 1:200 and then 1:19 with 0.9% NaCl. Control cells

received 25

0.9% NaCl plus 50 //I of DMSO diluted 1:19 with 0.9% NaCl. The final

concentration of DMSO in the incubation buffer was less than 0.05%. Glucose transport is

expressed as pmoles of glucose transported/ 106 cells. Bars represent the mean and brackets

the SEM of six observations.* p< 0.05 vs. control.
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(Figure 8A) in half of the experiments; while in the other half, All-stimulated glucose

transport was significantly reduced by 31.9% in the presence of PDB (Figure 8B).
To further examine the role of PKC in All-stimulated glucose transport, three
inhibitors of PKC were employed: staurosporine, calphostin C, and bisindoylmaleimide.
VSM cells were exposed to 50 nM staurosporine for one hour prior to the addition of AIL
All was capable of fully stimulating glucose transport in the presence of this nonspecific

PKC inhibitor (Figure 9). Calphostin C is considered to be a more specific inhibitor of PKC.
VSM cells were exposed to 200 nM calphostin C for one hour prior to the addition of AIL

In one experiment All was able to fully stimulate glucose transport in the presence of
calphostin C, while in another experiment All-stimulated glucose transport was reduced

(Table 3). Bisindoylmaleimide is also considered a specific inhibitor of PKC. VSM cells

were exposed to 100 nM BIM for 30 minutes prior to the addition of AH (Figure 10). All
was capable of fully stimulating glucose transport in the presence of BIM. In summary,

attempts to downregulate or inhibit PKC activity produced results that were somewhat
inconsistent; however, the preponderance of evidence supports the conclusion that All is

capable of stimulating glucose transport through a mechanism that is independent of PKC.
To determine whether extracellular calcium plays a role in mediating the effect of AH
on glucose transport, VSM cells were incubated in a calcium-free medium or in a medium

containing 1.8 mM CaCl2. Under conditions where basal transport was unaffected by the
medium calcium content, the rate of All-stimulated glucose transport was 2.5 times greater

in the medium containing 1.8 mM CaCl2 than in a medium containing no calcium (Figure
11). To determine if membrane integrity was compromised in the cells exposed to zero
46
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Figure 8

The effect of downregulating PKC with phorbol dibutyrate (PDB) on All

stimulated glucose transport. VSM cells were exposed to 1 //M PDB or diluent for 48 hours
prior to the addition of All or diluent for an additional six hours. Prior to adding All or
diluent, the medium was removed and replaced with fresh medium containing PDB or
diluent. The PDB was dissolved in dimethylsulfoxide (DMSO) to prepare a stock solution

of 10 mM (5 mg/ 1 ml). The PDB stock solution was diluted 1:200 with 0.9% NaCl and 50

//I aliquots were added to the incubation medium of cells to give a final concentration of 1
//M. The cells treated with PDB alone also received 25 //I of 0.9% NaCl. The All stock
solution (1 mg/ ml) was diluted 1:100 with 0.9% NaCl and 25 //I was added to the incubation
medium to give a final concentration of 100 nM. The cells treated with All alone also

received 50 //I of DMSO diluted 1:200 in 0.9% NaCl. Control cells received 25 //I of 0.9%

NaCl plus 50 //I of DMSO. The final concentration of DMSO in the incubation buffer was
less than 0.5%. Data are expressed as pmoles of glucose transported/ 106 cells. Bars

represent the mean and brackets the SEM of six observations. Panel A shows no effect on
All-stimulated glucose transport with PDB.

Panel B shows that PDB reduced All

stimulation of glucose transport. * p<0.05 vs. control; + p< 0.05 vs. AIL
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Figure 9

The effect of staurosporine (STAURO), a PKC inhibitor, on All-stimulated

glucose transport. VSM cells were exposed to 50 nM STAURO, 100 nM All, 50 nM

STAURO + 100 nM All, or diluent for six hours. STAURO was dissolved in DMSO to
prepare a stock solution of 1 mM (0.1 mg/ 0.214 ml). The stock solution was diluted 1:400

with 0.9% NaCl and 50 /A aliquots were added to the incubation medium to give a final

concentration of 50 nM one hour prior to the addition of All or vehicle. The cells treated
with STAURO alone also received 25 //I of 0.9% NaCl. The stock solution of All (1 mg/
ml) was diluted 1:100 with 0.9% NaCl and 25 //I aliquots were added to the incubation

medium to give a final concentration of 100 nM. The cells treated with All alone also
received 50 //I of DMSO diluted 1:400 with 0.9% NaCl. The control cells received 25 /d of
0.9% NaCl and 50 //I of DMSO diluted 1:400 with 0.9% NaCl. The final concentration of
DMSO in the incubation buffer was less than 0.05%. Results are expressed as pmoles of

glucose transported/ 106 cells.

Bars represent the mean and brackets the SEM of six

observations. * p< 0.05 vs. control
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The effect of calphostin C, a PKC inhibitor, on All-stimulated glucose

transport. VSM cells were exposed to 200 nM calphostin C or diluent for one hour prior to

the addition of 100 nM All or diluent for an additional six hours. The calphostin C was
dissolved in DMSO to make a 1 mM stock solution. The stock solution was diluted 1:50

with 0.9% NaCl and 25 //I aliquots were added to the incubation medium to give a final

concentration of 200 nM. The cells incubated with calphostin C alone also received 25 //I
of 0.9% NaCl. The All stock solution (1 mg/ ml) was diluted 1:100 with 0.9% NaCl and 25

//I aliquots were added to the incubation medium. The cells treated with All alone also

received 25 //I of DMSO diluted 1:50 with 0.9% NaCl. The control cells received 25 //I
0.9% NaCl and 25 //I of DMSO diluted 1:50 with 0.9% NaCl. In experiment 2, the cells

were exposed to direct fluorescent lighting during the one hour preincubation with calphostin
C or diluent; while in experiment 1, the cells were not. Results are expressed as percent
stimulation above control. * p< 0.05 vs. percent stimulation of All in the absence of

calphostin C.
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Figure 10

The effect of bisindoylmaleimide (BIM), a PKC inhibitor on All stimulated

glucose transport. Cells were exposed to 100 nM BIM or vehicle for 30 minutes prior to the

addition of 100 nM All or vehicle for an additional six hours. The BIM was dissolved in
DMSO to prepare a stock solution of 5 mM (2 mg/ ml). The stock solution of BIM was

diluted 1:49 with 0.9% NaCl, then further diluted 1:9 with 0.9% NaCl and 25 //I aliquots

were added to the incubation medium to give a final concentration of 100 nM. The cells

treated with BIM alone also received 25 //I of 0.9% NaCl. The All stock solution (1 mg/ ml)
was diluted 1:100 with 0.9% NaCl and 25 //I aliquots were added to the incubation medium
to give a final concentration of 100 nM. The cells treated with All alone also received 25

//I of DMSO diluted 1:49 then 1:9 with 0.9% NaCl. The control cells received 25 /zl 0.9%
NaCl and 25 //I of DMSO diluted 1:49 then 1:9 with 0.9% NaCl. The final concentration of
DMSO in the incubation buffer was less than 0.05%. Results are expressed as pmoles of
glucose transported/ 106 cells. Bars represent the mean and brackets the SEM of six

observations. * p< 0.05 vs. control.
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Figure 11

The effect of medium calcium concentration on All-stimulated glucose

transport. Cultured VSM cells were incubated in DMEM with either zero or 1.8 mM CaCl2
for eight hours.

Six hours prior to the end of the incubation period, All or an equivalent

volume of diluent were added to the incubation medium. The All stock solution (1 mg/ ml)

was diluted 1 TOO with 0.9% NaCl and 25 //I aliquots were added to the incubation medium.
Results are expressed as pmoles of glucose transported/ 106 cells. Bars represent the mean

and brackets the SEM of six observations. * p < 0.05 compared with corresponding control;

+P

0.05 compared with All-stimulation in a Ca2+-free medium.

54

T

400

300©

■ BASAL
E An

o
200<1>

©

Eex
100-

0

1.8 mM

ZERO

CALCIUM CONCENTRATION

55

calcium, cell viability and nonspecific glucose transport were assessed. Cell viability was
determined using trypan blue exclusion. Zero calcium did not alter percent viability of the

cells (Table 4). Nonspecific transport was examined by incubating cells in zero or 1.8 mM
CaCl2-containing medium with an excess of cytochalasin B to block specific glucose
transport. In studies where cytochalasin B was present in the incubation medium, there was
no change in the percent of glucose transport due to nonspecific uptake in cells incubated in
a medium containing zero or 1.8 mM CaCl2 (Table 4) suggesting that membrane integrity

was not compromised. These results emphasize the importance of extracellular calcium in
All-stimulated glucose transport.

Intracellular calcium binds calmodulin, a calcium binding protein. The calcium
calmodulin complex, in turn, is capable of mediating many cellular processes (Head, 1992;

O’Neil and DeGrado, 1990). To determine whether or not calmodulin is involved in All
stimulated glucose transport, VSM cells were incubated with All in the presence or absence

of 5 //M calmidazolium, a calmodulin inhibitor. Glucose transport in response to AH was
reduced 57% in the presence of calmidazolium (Figure 12) suggesting that calmodulin plays

a role in mediating All-stimulated glucose transport. This data is further supported by the
results of an experiment using a different calmodulin inhibitor, N-(6-aminohexyl)-5-chloro1-naphthalenesulfonamide (W-7, 50 //M). W-7 reduced All-stimulated transport by 46%

(Figure 13).
Since medium glucose concentration has been reported to affect hormone-induced

increases in glucose transport (Cooper et al., 1993), the effect of medium glucose
concentration on All-stimulated glucose transport was assessed (Figure 14). Clearly, basal
56
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Table 4

Medium calcium
concentration (mM)

Cell viability

Nonspecific
transport

0

53.5 ±7.1 %

4.6 ±0.96%

1.8

47.7 ±5.1 %

4.2 ±0.21 %

The effect of medium calcium concentration on cell membrane integrity.

Cultured VSM cells were incubated in DMEM with either zero CaCl2 or 1.8 mM CaCl2 for
eight hours. Cell viability was assessed using trypan blue exclusion and is expressed as the

percent of cells that are viable and was calculated as follows:

(number of cells excluding trypan blue + total number of cells) x 100.

Nonspecific glucose transport was measured using cytochalasin B to inhibit the glucose
transporter (refer to Methods: [3H]-2-deoxyglucose transport assay). The glucose transport

data is expressed as the percent of glucose uptake due to nonspecific transport and was

calculated as follows:

[(pmoles of glucose transported in the presence of cytochalasin B / 106 cells)
(pmoles of glucose transported in the absence of cytochalasin B / 106 cells)] x 100.
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Figure 12

The effect of calmidazolium, a calmodulin inhibitor, on All-stimulated

glucose transport. VSM cells were exposed to 5 //M calmidazolium (CDZ) or an equivalent

volume of vehicle for one hour prior to the addition of 100 nM All or vehicle for an
additional six hours. The CDZ was diluted with DMSO to prepare a stock solution of 1 mM

(5 mg/ 7.25 ml). The CDZ stock solution was diluted 1:1 with 0.9% NaCl and 25 pi\ aliquots
were added to the incubation medium to give a final concentration of 5 /^M.

The cells

treated with CDZ alone also received 25 //I 0.9% NaCl. The All stock solution (1 mg/ ml)

was diluted 1 TOO with 0.9% NaCl and 25 //I aliquots were added to the incubation medium
to give a final concentration of 100 nM. The cells treated with All alone also received 25

//I of 50% (v/v) DMSO in 0.9% NaCl. The control cells received 25 //I 0.9% NaCl and 25

//I of DMSO diluted 1:1 with 0.9% NaCl. The results are expressed as pmoles of glucose
transported /106 cells. Bars represent the mean and brackets the SEM of six observations.
* p< 0.05 vs control; + p< 0.05 vs AIL
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Figure 13

The effect of W(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide (W-7),

a calmodulin inhibitor, on All-stimulated glucose transport. VSM cells were exposed to 50
//M W-7 or vehicle for one hour prior to the addition of 100 nM All or vehicle for an

additional six hours. The W-7 was diluted with 10% DMSO to prepare a stock solution of
5 mM (3.1 mg/ 1.63 ml). The stock solution was then further diluted 1:1 with 11% DMSO

and 50 //I aliquots were added to the incubation medium to give a final concentration of 50

//M. The cells treated with W-7 alone also received 25 /.d 0.9% NaCl. The All stock
solution (1 mg/ ml) was diluted 1 TOO with 0.9% NaCl and 25 //I aliquots were added to the

incubation medium to give a final concentration of 100 nM. The cells treated with All alone
also received 50 //I of 10% DMSO in 0.9% NaCl. The control cells received 25 //I 0.9%
NaCl and 50 //I of 10% DMSO in 0.9% NaCl. The results are expressed as pmoles of

glucose transported /106 cells. Bars represent the mean and brackets the SEM of six
observations. * p< 0.05 vs control; + p< 0.05 vs AIL
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Figure 14

The effect of medium glucose concentration on All-stimulated glucose

transport. Cultured VSM cells were incubated for 18 hours in medium containing either 2.5
or 25 mM glucose prior to the addition of 100 nM All or an equivalent volume of diluent

(Basal) for an additional six hours. Transport is expressed as pmoles of glucose/ 106 cells.
Each point is the mean + the SEM of six replicates. *p< 0.05 vs. corresponding basal values;
+ p< 0.05 vs. All stimulation in 25 mM glucose medium.
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glucose transport was increased in cells exposed to a medium containing 2.5 mM glucose for

24 hours compared to cells incubated in a medium containing 25 mM glucose for the same
period of time. During the incubation period, the concentration of glucose in the 2.5 mM and
the 25 mM glucose media decreased by 92% and 20%, respectively (Table 5). Cell number

was not affected by medium glucose concentration (Table 5). While there was not an
appreciable change in the maximum level of glucose uptake achieved with All at different
glucose concentrations, the percent stimulation above basal transport with All was greater

in cells incubated in 25 mM glucose compared to those incubated in 2.5 mM glucose (Figure

14). Western blot analysis of GLUT 1 from cells incubated in 2.5 mM or 25 mM glucose
medium with or without All parallels the glucose transport data (Figure 15). The level of
immunoreactive GLUT 1 was less in cells exposed to 25 mM glucose as compared to those

exposed to 2.5 mM glucose. All increased immunoreactive GLUT 1 in cells exposed to 25
mM glucose to a greater extent than in cells exposed to 2.5 mM glucose.
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Predicted glucose
concentration (mM)

Incubation
time (hours)

Actual glucose
concentration (mM)

0

2.6 ±0.1

24

0.2 ±0.2

0

22.2 ± 1.7

24

17.8 ± 1.7

Cell number

2.5 mM
1.41xl06 ± 0.09

25 mM

Table 5

1.23xl06 ± 0.18

The effect of a 24 hour exposure to 2.5 mM and 25 mM glucose medium on

medium glucose concentration and cell number. VSM cells were incubated in medium
containing 2.5 mM or 25 mM glucose. The concentration of glucose in the stock medium

was measured for a time zero value. The concentration of glucose in the medium at the end
of the 24 hour incubation period was also measured. In addition, cell number was also

measured after a 24 hour exposure to 2.5 mM and 25 mM medium glucose.
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1

Figure 15

The effect of All on GLUT 1 protein levels from cells incubated in 2.5 mM

or 25 mM glucose medium. The cells were treated as in Figure 14 and crude membranes

were isolated and subjected to western blot analysis. Relative levels of GLUT 1 in the

experimental groups were assessed by densitometric analysis and expressed as arbitrary

units.
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DISCUSSION

The results of the present investigation support the hypothesis that All can help VSM
cells meet the increased metabolic demands of the growth processes that it initiates by

concurrently stimulating glucose transport. It is clear that All stimulates glucose transport

in these cultured cells in both a time- and dose-dependent manner (Figures 1 and 2).

It can also be concluded that All-stimulated glucose transport is initiated by the
binding of All to specific All receptors because All-stimulated glucose transport was

reduced by 90% in the presence of saralasin (Figure 3), a competitive inhibitor of All
binding. In addition to being a competitive inhibitor of All binding, saralasin, [(1-sarcosine,

8-threonine) All], also exhibits partial agonist activity. It was selected for this study
primarily because its agonist activity is low relative to other available receptor antagonists.

This was demonstrated by Munoz-Ramirez (1976) and colleagues who examined a variety
of one- and eight- position amino acid substituted analogs that are routinely used as All
receptor antagonists. They showed that saralasin was a potent antagonist for the All receptor

in the presence of All even though it exhibited partial agonist activity when used by itself.
Of the receptor antagonists that they examined, saralasin had the lowest level of agonist

activity. The very modest stimulation of glucose uptake by saralasin alone in the present

study (Figure 3) is consistent with this observation.
The involvement of protein synthesis in All stimulation of glucose transport was also

examined. The concentration of cycloheximide, a potent inhibitor of protein synthesis, used

to affect All-stimulated glucose transport was in the concentration range (0.5 //g/ ml) used
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by others to inhibit glucose transport in different tissues as opposed to larger concentrations
(50 //g/ ml) which affect transporter synthesis as well as transporter degradation (Yamada
et al., 1983). Cycloheximide reduced All-stimulated glucose transport by 70% (Figure 4),

suggesting that glucose transport in response to a six hour exposure to All involves new

protein synthesis. In some, but not all experiments with cycloheximide, a small, yet
significant increase in basal transport was also observed. This is consistent with the

observations of others. Significant stimulation of glucose uptake has been observed in
several cell lines in response to large concentrations of cycloheximide (Clancy et al., 1991;

Jones and Cushman, 1989). Because cycloheximide-induced cell death could explain the
reduction in All-stimulated glucose uptake in response to cycloheximide, cell viability was
assessed under the experimental conditions used to examine the effect of cycloheximide on

glucose transport. Cycloheximide treatment did not reduce cell viability as assessed by
trypan blue exclusion (84.7% viable for control and 92.3% viable for cycloheximide). In

summary, the results of these studies suggest that All increases glucose transport at least in

part through a mechanism that requires protein synthesis.

Further support for the role of protein synthesis in All-stimulated glucose uptake is
provided by the observation that All increased the level of a specific protein, the GLUT 1

transporter, in VSM cells (Figure 6). Many investigators have reported an increase in
glucose transport that can be attributed to mechanisms involving an increase in GLUT 1

protein levels (Haspel et al., 1986; Kaiser et al., 1993). One must also consider the
possibility that an increase in immunoreactive GLUT 1 transporter could be due to a

reduction in GLUT 1 degradation as opposed to synthesis. The western blot analysis study
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did not delineate the precise mechanism responsible for the increase in GLUT 1 protein

levels.

All elicits a cellular response by binding to specific plasma membrane receptors. The

binding of All to the AT] receptor in vascular smooth muscle activates phospholipase C via
a G-protein mediated mechanism (Duff et al., 1995).

Phospholipase C hydrolyzes

phosphatidylinositol 4,5-bisphosphate to inositol trisphosphate and diacylglycerol
(Alexander et a ., 1985; Griendling et al., 1986). This, in turn, leads to a rise in intracellular
Ca2+ (Brock et al., 1985) and the activation of PKC (Griendling et al., 1989; Williams and

Schrier, 1992). The present investigation examined the role of PKC, extracellular calcium,
and calmodulin in mediating All-stimulated glucose transport in cultured VSM cells.

Three separate experimental designs were used to assess the role of PKC in All

stimulated glucose transport. In one experiment PKC was activated by the addition of
phorbol esters to the incubation medium. In a second, PKC was downregulated by prolonged

exposure to phorbol esters prior to All stimulation. In a third, PKC activity was inhibited

using specific inhibitors.
Since phorbol esters are known to promote PKC activity by binding to the

diacylglycerol (DAG) binding site of the PKC molecule (Newton, 1995), these agents were
used to stimulate PKC activity in VSM cells in the present study. A six hour exposure of

VSM cells to the phorbol esters PMA and PDB resulted in an increase in glucose uptake,
suggesting that glucose transport can be stimulated by the activation of PKC (Figure 7).

Using these same experimental conditions, other researchers have directly shown that PKC
activity is increased. Williams and Schrier (1992) exposed cultured VSM cells to 1 //M and
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100 //M PM A for six hours and observed a significant increase in PKC activity.
Additionally, Longo (1992) and colleagues demonstrated that 100 nM PDB increased
glucose transport in human cultured skin fibroblasts after a six hour exposure. Even in light
of these observations, however, a conclusion from the present study that PKC is involved in

mediating All-stimulated glucose transport must be regarded with considerable caution for
several reasons. First, even though the phorbol esters stimulated glucose uptake, there was

no simultaneous measurement of phorbol ester stimulation of PKC activity. Moreover, the
use of phorbol esters to activate PKC does not reliably indicate PKC involvement in an All

mediated response in that it has been observed that phorbol esters are more potent activators

of PKC than the physiological activator, diacylglycerol (Newton, 1995). Further, phorbol
esters can activate PKC independently of calcium (Rasmussen et al., 1995).

The

conventional PKC isoforms (a, ph pn, y) require both DAG and calcium for activation
whereas the novel (6, e, 0, p, r|) PKC isoforms require DAG but not calcium for activation.

A third category of PKC, the atypical isoforms ((, X, i), require neither DAG nor calcium

for activation. Therefore, treatment with phorbol esters (a pharmacological activator of
PKC) may demonstrate a positive cellular response via activation of PKC isoforms that are

not normally activated by the agonist in question.
To further examine the potential role of PKC in mediating glucose uptake in response

to All, VSM cells were treated chronically with PDB to reduce cellular PKC levels. This
treatment is thought to prevent PKC activation by an agonist due to the relative lack of PKC.

The involvement of PKC in the All response was not clearly delineated in this study, in part,
because the numerous PKC downregulation experiments produced variable results. In some
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experiments, a 48 hour exposure of VSM cells to PDB partially suppressed All-stimulated

glucose uptake, whereas in other experiments PDB did not have an effect on this parameter

(Figure 8). The dichotomy of results can be interpreted in light of two hypotheses: 1) the
treatment employed in this study may not fully downregulate all PKC isoforms and 2) there

may be differences in the responsiveness of cell populations to the treatment.

I

Addressing the first hypothesis, McCumbee and colleagues (1996) demonstrated that

I

a 48 hour exposure to 50 nM PDB significantly reduced, but did not abolish, the level of

immunoreactive PKC a in cultured VSM cells. It is possible that the PKC a remaining after

the treatment was sufficient to fully stimulate glucose transport in response to AIL Also,
VSM cells express several PKC isoforms including a, p, e, and £ (Williams, 1995). The

susceptibility to downregulation is different for some of the individual isoforms. For
instance, PKC £ is not downregulated by chronic phorbol ester exposure (Huwiler et al.,

1992). It is possible that when an isoform that is normally activated by All is not present in
a quantity sufficient to accomplish the effect or is inhibited, another PKC isoform might be

activated to accomplish the task.
The above results are also consistent with the hypothesis that cultures derived from

vascular smooth muscle yield subpopulations of cells that vary in their responses to a specific
experimental manipulation (Kimes and Brandt, 1976; Absher et al., 1989). The experiments

presented throughout this project were performed a number of times using cells derived from
different populations. In three separate cell populations, exposure of cells to PDB to

downregulate PKC did not affect All-stimulated glucose transport. In three additional and

separate cell populations, PDB downregulation did reduce glucose uptake in response to AIL
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I
These results may reflect the resistance of some populations of VSM cells to PKC
downregulation with phorbol esters , as well as reflecting the possibility that in some cell

populations All-stimulated glucose transport can be achieved via a PKC-independent
pathway. The data also suggest, at least in some VSM cell populations, that full expression

of All-stimulated transport requires PKC activation. While PKC downregulation appears

to be a nice approach to assessing the involvement of PKC in intracellular events, the data

must be interpreted with caution. As Rasmussen and colleagues (1995) have suggested,
chronic phorbol ester treatment or downregulation of PKC likely results in

pharmacologically altered cells that may respond nonphysiologically to specific stimuli.
I

Given the nature of the treatment and the dichotomy of results obtained from the
experiments, downregulation of PKC by PDB does not appear to be a very reliable technique
in the context of this study.
PKC inhibitors were used in an attempt to provide a better assessment of the

involvement of PKC activation in All stimulation of glucose transport.

Using the

nonspecific PKC inhibitor, staurosporine, All-stimulated glucose transport was not affected

(Figure 9). It is possible that the 50 nM concentration used in the studies was not enough to
fully inhibit PKC. However, Baldo (1995) and colleagues were able to significantly inhibit

PKC-mediated triglyceride synthesis in human skin fibroblasts in response to PMA using a
six hour exposure to 50 nM staurosporine. While higher concentrations of staurosporine

might have achieved a complete reduction in All stimulation of glucose transport in the

present experiment (Figure 9), basal transport would also be reduced since the concentration
of staurosporine used in this study already reduced basal transport by approximately 30%.
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Such an alteration in baseline transport would further compromise a meaningful

interpretation of the data.

Calphostin C was used as an additional PKC inhibitor to complement the preceding
study. The results, however, were not conclusive (Table 3). In one experiment, calphostin
C did not have an effect on All-stimulated glucose uptake when measures were taken to
prevent its exposure to light. In contrast, calphostin C significantly reduced All-stimulated
transport when the inhibitor was light-activated. VSM cells were exposed to calphostin C

for one hour in direct fluorescent lighting prior to the addition of All to induce light
activation. In that PKC activity was not directly measured in these experiments, it is not
clear whether calphostin C requires light-activation in order to be effective. Some studies
indicate that calphostin C needs to be light-activated before it can inhibit PKC (Ali et al.,

1994).

On the other hand, many studies, including the original paper describing the

specificity of calphostin C for PKC (Kobayashi et al., 1989), do not indicate that light

activation is necessary for calphostin C to function effectively as a PKC inhibitor. In

addition, studies have successfully used calphostin C to inhibit PKC-mediated responses in
whole arteries (Henrion et al., 1992; Shimamoto et al., 1993) and cultured vascular smooth

muscle cells (Rao et al., 1994) without specifying light-activation in the protocol.
Bisindoylmaleimide (BIM), another specific PKC inhibitor, was also employed in

this investigation. As shown in Figure 10, 100 nM BIM did not alter All-stimulated glucose

transport.

To summarize the PKC inhibitor studies, staurosporine and BIM did not

significantly alter All-stimulated transport. The evidence derived from the calphostin C

studies was not conclusive. Even so, the results gained using two inhibitors, staurosporine
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and BIM, support the conclusion that All can stimulate glucose transport independently of
PKC.

Taken together, the majority of the evidence from the PKC downregulation and the
PKC inhibitor studies suggests that All is capable of stimulating glucose transport through
a mechanism independent of PKC. Of the two mechanisms employed, PKC inhibition is

probably the most reliable indicator of PKC involvement in a given response. PKC

downregulation requires a prolonged exposure (forty-eight hours) to PDB and likely results
in a pharmacologically and physiologically altered cell. PKC inhibitor studies require a
shorter exposure (six hours) of the cells to the inhibitor.

The staurosporine data

demonstrated that All-stimulated glucose transport was not altered. However, staurosporine
does not discriminate among protein kinases and binds the catalytic domain of PKC which

is common to protein kinases (Tamaoki et al., 1986). Calphostin C is a more specific

inhibitor of PKC, binding to the regulatory domain of the enzyme (Kobayashi et al., 1989).

Bisindolylmaleimide is a PKC inhibitor that is structurally related to staurosporine but is
very selective for PKC (Toullec et al., 1991). The use of calphostin C did not appear to be
productive as it gave conflicting results.

The use of BIM as a more specific inhibitor of

PKC supported the data obtained using staurosporine.
To further investigate the signaling mechanisms involved in All-stimulated glucose

transport, the role of extracellular calcium was assessed by incubating VSM cells in medium
with zero CaCl2 or 1.8 mM CaCl2. While there is evidence suggesting that All causes a rapid

rise in intracellular calcium through the release of stored intracellular calcium (Alexander
et al., 1985), evidence also supports the role of extracellular calcium in maintaining a plateau
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phase of elevated intracellular calcium in response to All (Brock et al., 1985). The results

presented support the hypothesis that extracellular calcium is important for All-stimulated

glucose transport (Figure 11) in that there was a significant attenuation of glucose uptake in
response to AU in the absence of extracellular calcium. Occasionally, basal transport was

significantly increased in cells incubated in medium with zero calcium. All did not further
stimulate glucose transport in these cells.

It is possible that cell permeability was

compromised, due to the relative lack of calcium, leading to a leaky cell membrane. In such
a case, the increase in basal transport could be due to glucose entering the cells through

nonspecific transport; however, this did not appear to be the case. There was no difference

in the percent of glucose transport due to nonspecific uptake in cells incubated in medium

containing zero CaCl2 or 1.8 mM CaCl2 (Table 4). These results suggest that the occasional
increases in basal transport seen in the absence of extracellular calcium were not simply due
to a leakiness of the membrane. Further, zero calcium did not alter percent viability of the
cells as evidenced by the capacity of cells in zero CaCl2 to exclude trypan blue as effectively
as cells in 1.8 mM CaCl2 (Table 4).

One mechanisms through which intracellular calcium can alter cellular function is
via the activation of calmodulin (Head, 1992; O’Neil and DeGrado, 1990). Evidence
supports a role for Ca27calmodulin in All-stimulated processes in VSM cells (Kubalak and
Webb, 1993; Nantel et. al., 1991). Calmodulin-dependent processes can be blocked using
calmodulin inhibitors, such as W-7 (Hidaka et al., 1981) and calmidazolium (Gietzen et al.,

1981).

The concentrations of inhibitors used in this study were consistent with

concentrations used by other investigators (Gietzen et. al., 1981; Kindmark et al., 1995;
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Hidaka et al., 1981).

Both inhibitors (Figures 12 and 13) significantly reduced All-

stimulated glucose uptake in the present study, suggesting that calmodulin is involved in All
stimulation of glucose transport.

Medium glucose has been shown to affect basal glucose transport in many cell lines,
including cultured chicken embryo fibroblasts (Kletzien and Perdue, 1975), cultured diploid

human skin fibroblasts (Germinario et al., 1982), and cultured L6 muscle cells (Koivisto et
al., 1991). In addition, Cooper and associates (1993) have observed changes in hormone-

induced glucose transport with changes in medium glucose concentration using A-10
vascular smooth muscle cells. The current investigation demonstrates that basal glucose

transport increases when medium glucose concentrations decrease (Figure 14). GrecoPerotto et al. (1992) and Yamada et al. (1983) have reported similar observations using L8
myocytes and chicken embryo fibroblasts, respectively. In addition, the percent stimulation

of glucose transport by All is considerably less in a low glucose medium than in a high

glucose medium. The data suggest that the maximum rate of glucose transport in response
to All does not change appreciably with various glucose concentrations and that the relative
effectiveness of All at different concentrations of glucose is a function of glucose

concentration on the transport process. This conclusion is supported by the observation that

the GLUT 1 transporter level mimics that of the glucose transport activity in response to All
and glucose levels (Figure 15).
The western blot experiments presented within this study used the anti-GLUT 1

antibody (3406 GLUT 1 Ab) to detect the GLUT 1 transporter. This antibody was prepared

in the laboratory and appears to be specific for the GLUT 1 transporter. Enzyme-linked
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immunosorbent analysis demonstrated that the 3406 GLUT 1 Ab reacted strongly with the

GLUT 1 peptide and not the GLUT 2, GLUT 4, and GLUT 7 peptides (Table 2). Additional

support for the recognition of GLUT 1 by the 3406 GLUT 1 Ab stems from studies using red

blood cell membranes as positive controls during western blot analysis of VSM cell
membranes (Figure 5). Red blood cell membranes are enriched in GLUT 1 transporters

(Carruthers, 1990). The 3406 GLUT 1 Ab recognized protein bands from both sources of

membranes that correspond with published molecular weights for GLUT 1 (Gorga, et al.,

1979; Kumagai, et al., 1994). The recognition of more than one protein band by GLUT 1
Ab can be explained. The GLUT 1 transporter has a sugar moiety bound to it which
accounts for almost one-fourth of the molecular mass of GLUT 1 (Gorga, et al., 1979).
Glycosylated GLUT 1 has been reported to run as a broad band of 45- to 60-kDa (Asano, et

al., 1991). Other investigators have reported apparent molecular weights of 52-kDa and 55-

kDa for glycosylated GLUT 1 and 38-kDa (Asano, et al., 1991), 42-kDa, and 46-kDa
(Kumagai, et al., 1994; Gorga, et al., 1979) for deglycosylated GLUT 1. It is possible that
the two protein bands detected by 3406 GLUT 1 Ab represent glycosylated and

deglycosylated GLUT 1. Occasionally, 1:1,000 dilutions of 3406 GLUT 1 Ab detected a
protein band with a molecular weight of approximately 30-kDa which could possibly
represent a partially degraded GLUT 1.

In summary, this research project has provided evidence that All stimulates glucose
transport in cultured VSM cells in a time and concentration-dependent manner.

All

stimulation of glucose transport was protein synthesis dependent and resulted in an increase

in the membrane GLUT 1 transporter content. The evidence presented supports a role of
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extracellular calcium and calmodulin in mediating intracellular events leading to increased
glucose transport in response to All. While the role of PKC is less clear, the evidence
suggests that All is capable of stimulating glucose transport through a mechanism

independent of PKC. The medium glucose concentration affected both basal glucose
transport and the magnitude of the response to AIL The rate of basal transport decreases

with increasing media glucose content. The magnitude of the response to All appeared to

increase with increasing glucose content of the incubation medium, whereas the maximum
level of glucose transport did not change appreciably. This can probably be explained in
light of the observation that media glucose concentration affects the basal rate of transport.

With increasing medium glucose concentration, the rate of basal transport decreases while
the maximum level of glucose transported in response to All remains unchanged. Therefore,

the actual percent stimulation in response to All increases with increasing medium glucose

content. The decrease in glucose transport into the cell with increasing extracellular glucose
content may be a protective mechanism to prevent the excessive glycosylation of cellular

proteins in vascular smooth muscle during hyperglycemic states like diabetes mellitus. If
this is indeed the case, then the response of vascular smooth muscle cells to All in a

hyperglycemic environment could lead to some potentially serious deleterious effects within

the cell and contribute even further to the pathogenesis of hypertension. It is interesting to
note that diabetic patients are more commonly hypertensive than nondiabetic patients. This
relationship may reflect the interaction of hyperglycemia and the factors that lead to

hypertension in the absence of hyperglycemia.
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APPENDIX A

TIME COURSE OF [3H]-2-DEOXYGLUCOSE UPTAKE

TIME (minutes)

pmoles glucose transported/ 106 cells

10

231.12 ± 8.52

20

387.99 ± 15.56

30

499.81 ±32.99

60

664.51 ±42.20
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APPENDIX B

NONSPECIFIC GLUCOSE TRANSPORT MEASUREMENTS

% OF TOTAL*

TREATMENT

EXPERIMENT 1
0 nM All

3.51 ±0.10

0.10 nM All

7.10 ±0.45

1.0 nM All

2.73 ±0.12

10 nM All

3.04 ±0.29

100 nM All

2.13 ± 1.07

1000 nM All

3.84 ±0.26

EXPERIMENT 2
Control

3.01 ±0.53

100 nM Saralasin

3.36 ±0.42

100 nM All

2.63 ±0.30

100 nM Saralasin
+ 100 nM All

3.63 ±0.67

EXPERIMENT 3

Control

4.15 ±0.04

1 //M CHX

2.88 ±0.05

100 nM All

2.35±0.16

1 /^M CHX
+ 100 nM All

2.94 ±0.13

Continued....

94

APPENDIX B, continued

% OF TOTAL*

TREATMENT

EXPERIMENT 4

Control

2.98 ±0.50

100 nM PDB

2.60 ±0.09

100 nM All

2.26 ±0.31

100 nM PDB
+ 100 nM All

2.78 ±0.45

EXPERIMENT 5

Control

2.56 ±0.09

50 nM Staurosporine

3.61 ±0.26

100 nM All

3.30 ±0.08

50 nM Staurosporine
+ 100 nM All

2.24 ±0.12

EXPERIMENT 6

2.5 mM glucose

3.56 ±0.52

2.5 mM glucose
+ 100 nM All

3.78 ±0.84

25 mM glucose

3.10±0.39

25 mM glucose
+ lOOnM All
* [nonspecific transport
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3.56 ± 0.15

total transport] x 100

APPENDIX C

SINGLE LETTER ABBREVIATIONS OF THE AMINO ACIDS

AMINO ACID

SINGLE LETTER
ABBREVIATION

AMINO ACID

SINGLE LETTER
ABBREVIATION

alanine
Arginine
Asparagine
Aspartate
Cysteine
Glutamate
Glutamine
Glycine
Histidine
Isoleucine

A
R
N
D
C
E
Q
G
H
I

Leucine
Lysine
Methionine
Phenylalanine
Proline
Serine
Threonine
Tryptophan
Tyrosine
Valine

L
K
M
F
P
S
T
W
Y
V

From: Halkerston, 1988.
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APPENDIX D

DMEM # 12430 FORMULATION

COMPONENT

mg/L

CaCl2 (anhydr.)

200.00

Fe (NO3)3 • 9H2O

0.10

KC1

400.00

MgSO4 (anhydr..)

97.67

NaCl

4750.00

NaHCO3

3700.00

Na2HPO4-H2O

125.00

D-Glucose

4500.00

HEPES

5958.00
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APPENDIX E

SYNTHETIC PEPTIDE CROSS-REACTIVITY WITH
A 1:1,000 DILUTION OF THE 3406 GLUT 1 Ab
Optical density measurements*
Synthetic peptide

3406 GLUT 1 Ab

Commercial GLUT 1 Ab

GLUT 1

+0.396

+ 1.057

GLUT 2

-0.234

-0.561

GLUT 4

-0.290

-0.268

GLUT 7

-0.445

-0.281

* corrected for nonspecific antibody binding
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